Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice

被引:10
|
作者
Xia, Jun [1 ]
Wang, Lingling [1 ]
Zhou, Xin [1 ]
Wang, Jing [1 ]
Wang, Huan [1 ]
Guo, Hongfeng [1 ]
机构
[1] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Hematol, 299 Qingyang Rd, Wuxi 214023, Peoples R China
关键词
Elderly; multiple myeloma; early mortality; bortezomib; International Staging System; lactate dehydrogenase; CLINICAL-FEATURES; STAGING SYSTEM; THERAPY; AGE; MANAGEMENT; SURVIVAL;
D O I
10.1177/0300060518757640
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. Methods Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to July 2015 were analyzed in a single hematology center. EM was defined as death of any cause within 12 months after diagnosis. A multivariate regression model was used to evaluate EM. Results EM occurred in 16 (14.8%) elderly patients with newly diagnosed MM. The most common cause of death was infection (10/16, 62.5%). In the multivariate analysis, only an age of 75 years, International Staging System (ISS) stage III disease, and high lactate dehydrogenase concentration were significantly and independently associated with EM. Conclusion Our results suggest that infection is the leading cause of EM in elderly patients with MM. An age of 75 years, ISS stage III disease, and a high lactate dehydrogenase concentration are significant predictors of EM. We should further target this higher-risk patient population to define personalized therapy with which to improve outcomes.
引用
收藏
页码:2230 / 2237
页数:8
相关论文
共 50 条
  • [41] REAL-WORLD MANAGEMENT AND OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA IN ROMANIA AND POLAND
    Dytfeld, D.
    Coriu, D.
    Fink, L.
    Hemetsberger, M.
    Bjorklof, K.
    Toka, K. S.
    Gatta, F.
    Niepel, D.
    VALUE IN HEALTH, 2017, 20 (09) : A459 - A460
  • [42] UNDERSTANDING THE REAL-WORLD CLINICAL CHARACTERISTICS OF MULTIPLE MYELOMA PATIENTS IN EUROPE
    Bacon, T.
    Gaudig, M.
    Ito, T.
    Hadfield, A.
    Rider, A.
    HAEMATOLOGICA, 2017, 102 : 529 - 529
  • [43] Real-world outcomes of venetoclax refractory multiple myeloma patients.
    Maples, Kathryn T.
    Kaufman, Jonathan L.
    Gupta, Vikas Anand
    Joseph, Nisha
    Heffner, Leonard T.
    Hofmeister, Craig C.
    Dhodapkar, Madhav, V
    Matulis, Shannon M.
    Boise, Lawrence
    Lonial, Sagar
    Nooka, Ajay K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] SEQUENTIAL TREATMENT REGIMENS FOR ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A COST-EFFECTIVENESS ANALYSIS INCLUDING EXPERIENCE FROM REAL-WORLD DATA
    Rochau, U.
    Vukicevic, D.
    Angerer, S.
    Schaffner, M.
    Rushaj, Qerimi, V
    Conrads-Frank, A.
    Jahn, B.
    Hackl, W. O.
    Ammenwerth, E.
    Stummer, H.
    Garrison, L. P.
    Weger, R.
    Willenbacher, E.
    Willenbacher, W.
    Siebert, U.
    VALUE IN HEALTH, 2019, 22 : S467 - S467
  • [45] Real-world economic outcomes of early progression in newly diagnosed multiple myeloma (NDMM) patients (Pts).
    Clancy, Zoe
    Pandya, Shivani
    Shrestha, Sulena
    Wang, Li
    Baser, Onur
    Ni, Quanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
  • [46] TREATMENT VARIATION COMPLICATES REAL-WORLD PHARMACOECONOMICS: DAILY CLINICAL PRACTICE OF BORTEZOMIB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Franken, M.
    Gaultney, J.
    Huijgens, P.
    Redekop, W. K.
    Uyl-de Groot, C. A.
    VALUE IN HEALTH, 2009, 12 (07) : A225 - A225
  • [47] Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Kastritis, Efstathios
    Brunaldi, Larissa
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Yong, Kwee
    Mactier, Catriona
    Corona, Magdalena
    Saez Marin, Adolfo Jesus
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Chhabra, Saurabh
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    BLOOD, 2023, 142
  • [48] Real-World Treatment Patterns from the HUMANS Study in Multiple Myeloma in Denmark
    Abildgaard, Niels
    Waage, Anders
    Hansson, Markus
    Anttila, Pekka
    Szilcz, Mate
    Ma, Yuanjun
    Rubin, Katrine Hass
    von Arx, Lill-Brith
    Orstavik, Sigurd
    Bent-Ennakhil, Nawal
    Freilich, Jonatan
    Gavini, Francois
    Green, Anders
    BLOOD, 2019, 134
  • [49] Minimal Residual Disease Perception and Utilization in Real-World Multiple Myeloma Treatment
    Jennings, Luke
    Gajra, Ajeet
    Balijevic, Muhamed
    Smith, Yolaine
    Feinberg, Bruce
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S425 - S426
  • [50] Osteonecrosis of the jaw secondary to bisphosphonate treatment in multiple myeloma - real-world data
    Vanhinsbergh, L.
    Husain, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 246 - 246